These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34156643)

  • 1.
    Roth BM; DePalma RM; Cook ME; Varney KM; Weber DJ; Ogretmen B
    Biomol NMR Assign; 2021 Oct; 15(2):383-387. PubMed ID: 34156643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PP2A is activated by cytochrome
    Casado-Combreras MÁ; Rivero-Rodríguez F; Elena-Real CA; Molodenskiy D; Díaz-Quintana A; Martinho M; Gerbaud G; González-Arzola K; Velázquez-Campoy A; Svergun D; Belle V; De la Rosa MA; Díaz-Moreno I
    Comput Struct Biotechnol J; 2022; 20():3695-3707. PubMed ID: 35891793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
    Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
    EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide in the prostate.
    Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
    Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
    Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).
    Jiang SW; Xu S; Chen H; Liu X; Tang Z; Cui Y; Liu J
    Clin Chim Acta; 2017 Jan; 464():155-159. PubMed ID: 27836688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the PP2A activity by the histone chaperone ANP32B is long-range allosterically regulated by respiratory cytochrome c.
    Rivero-Rodríguez F; Díaz-Quintana A; Velázquez-Cruz A; González-Arzola K; Gavilan MP; Velázquez-Campoy A; Ríos RM; De la Rosa MA; Díaz-Moreno I
    Redox Biol; 2021 Jul; 43():101967. PubMed ID: 33882408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
    Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
    Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
    Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
    FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for inhibition of the histone chaperone activity of SET/TAF-Iβ by cytochrome c.
    González-Arzola K; Díaz-Moreno I; Cano-González A; Díaz-Quintana A; Velázquez-Campoy A; Moreno-Beltrán B; López-Rivas A; De la Rosa MA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9908-13. PubMed ID: 26216969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
    Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
    Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.
    Shu G; Zhang L; Jiang S; Cheng Z; Wang G; Huang X; Yang X
    Oncotarget; 2016 Jun; 7(26):40285-40296. PubMed ID: 27244888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
    Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
    Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protein level of the tumour-promoting factor SET is regulated by cell density.
    Kohyanagi N; Kitamura N; Tanaka K; Mizuno T; Fujiwara N; Ohama T; Sato K
    J Biochem; 2022 Mar; 171(3):295-303. PubMed ID: 35076073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.